©The Author(s) 2025.
World J Gastrointest Endosc. Jun 16, 2025; 17(6): 104539
Published online Jun 16, 2025. doi: 10.4253/wjge.v17.i6.104539
Published online Jun 16, 2025. doi: 10.4253/wjge.v17.i6.104539
Table 2 Diagnostic modalities including computed tomography scan and endoscopic ultrasonography details
| Variable | Frequency (No.) | Percentage (%) |
| Total | 14 | 100.0 |
| CT scan status | ||
| Yes | 13 | 92.9 |
| No | 1 | 7.1 |
| CT scan successfully identifies lesion | ||
| Yes | 13 | 100.0 |
| EGD | ||
| Yes | 1 | 7.1 |
| No | 13 | 92.9 |
| Indication for EUS based on CT and EGD findings | ||
| Pancreatic mass | 6 | 42.9 |
| Pancreatic cyst | 1 | 7.1 |
| Pancreatic tail lesion and ductal dilation | 1 | 7.1 |
| Porta hepatis mass | 2 | 14.3 |
| Paraduodenal lesion | 1 | 7.1 |
| Liver lesion | 1 | 7.1 |
| Mediastinal lymphadenopathy | 1 | 7.1 |
| Extrinsic mass compressing pyloric area | 1 | 7.1 |
| EUS diagnosis | ||
| EUS guided FNB | 14 | 100.0 |
| Complications | 0 | 0.0 |
| EUS procedure’s setting | ||
| Endoscopy suite | 13 | 92.9 |
| In-patient | 1 | 7.1 |
- Citation: Ayesha S, Karim MM, Shahid AH, Rehman AU, Uddin Z, Abid S. Diagnostic role of endoscopic ultrasonography in defining the clinical features and histopathological spectrum of gastroenteropancreatic neuroendocrine tumors. World J Gastrointest Endosc 2025; 17(6): 104539
- URL: https://www.wjgnet.com/1948-5190/full/v17/i6/104539.htm
- DOI: https://dx.doi.org/10.4253/wjge.v17.i6.104539